Jayshree Dawane

Dr. Jayshree Dawane

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2023 in Toxicology Reports
Verified
Journal Article
Open access
DLDeepak Langade
Deepak Langade
JDJayshree Dawane
Jayshree Dawane
PDPriti Dhande
Priti Dhande
Withania somnifera (ashwagandha, WS) is widely used in traditional Indian Ayurvedic medicine. Studies indicate ashwagandha possesses antioxidant, anxiolytic, memory enhancing, antiparkinsonian, anti-venom, anti-inflammatory and antitumor properties. Present study evaluated the sub-acute toxicity of repeated dose administration of Ashwagandha root extract in wistar rats. Sub-acute toxicity of Ashwagandha was done as per the OECD-407 guidelines and was carried out for 28 days where satellite group was observed for 43 days. Wistar rats, 30 male and 30 females, were included in the study with 10 [5 M, 5 F] animals per group. Laboratory procedures were performed in accordance with CPCSEA guidelines. Animals were housed in standard laboratory conditions and were administered drugs orally- vehicle to control group and Ashwagandha 200, 400, 800 mg/kg body weight/day to study group. General parameters were noted, blood collection was done for haematological and biochemical parameters. All the animals were sacrificed, dissected and observed for gross necropsy and organs of high dose groups from control and Ashwagandha groups were sent for Histopathological examination. Gradual weight gain was observed in all the animals. No signs of intoxication and no changes in blood biochemistry were observed. Histopathological changes in organs were within normal limits. After repeated dose administration, Ashwagandha root powder extract did not show any major abnormality in a dose 5 times of the recommended human dose and above upto 800 mg/kg.

31 December 2024 in Preventive Nutrition and Food Science
Verified
Journal Article
Open access
PDF file
JDJayshree Dawane
Jayshree Dawane
SSSanghee Seok
Sanghee Seok
PDPriti Dhande
Priti Dhande
DLDeepakkumar Langade
Deepakkumar Langade
HHHwana Han
Hwana Han
JJJae-Yeong Ju
Jae-Yeong Ju
Jayshree Dawane, Sanghee Seok, Priti Dhande, Deepak Langade, Hwana Han, Sang-Back Kim, and Jae-Yeong Ju. Prev Nutr Food Sci 2024;29:414-21. https://doi.org/10.3746/pnf.2024.29.4.414

30 November 2024 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
VPVijaya Anil Pandit
Vijaya Anil Pandit
SSSharwan Kumar Singhal
Sharwan Kumar Singhal
GDGourav Bharat Deshmane
Gourav Bharat Deshmane
RSRanjana Ajit Sahasrabuddhe
Ranjana Ajit Sahasrabuddhe
MKManjiri Neelkanth Karandikar
Manjiri Neelkanth Karandikar
Asmita WeleAsmita Wele
Asmita Wele
Introduction: The Bhasmas, herbo-minerals, are reported to produce adverse effects when used clinically. Therefore, the present study aimed to assess the safety of Krishna Vajra Abhraka Bhasma (KVB), through acute and subacute toxicity testing. Materials and Methods: After ethics committee approval, total 66 Wistar albino rats weighing 180-200 gms were used. Experiments were conducted as per CCSEA guidelines. In acute toxicity study, a single limit dose of 2000 mg/kg of KVB with honey was administered to six female rats. Subacute toxicity studies involved 60 Wistar albino rats of either sex, randomly divided into six groups and received KVB in low (highest clinical dose extrapolated to rats), medium (double the low dose) and high (double the medium dose) dose administered orally for 28 days. Results: No mortality or adverse effects on rat's general behaviour or internal organs was observed in acute toxicity study The results of subacute study indicated no significant differences in body and organ weights, hematological or renal function between control and treated groups. However, mid and high doses of KVB revealed reversible, dose-dependent hepatotoxicity through biochemical and histopathological evaluation, while the satellite high dose group did not exhibit this effect, confirming it as drug-induced hepatotoxicity. Conclusion: The acute toxicity results positioned KVB in class V (safe) of the GHS classification. Subacute toxicity findings suggested that while low therapeutic doses were non-toxic, mid and high doses induced reversible hepatotoxicity, emphasizing the importance of careful dosage considerations and patient monitoring in Ayurvedic practice. The study contributes valuable insights into the safety profile of KVB, addressing concerns for both users and practitioners of Ayurvedic medicine.

31 March 2026 in Current Issues in Pharmacy and Medical Sciences
Verified
Journal Article
Open access
JDJayshree Dawane
Jayshree Dawane
SSSonali Suryawanshi
Sonali Suryawanshi
HJHarshita Jain
Harshita Jain
PDPriti Dhande
Priti Dhande
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent that may induce acute kidney injury (AKI), posing a major clinical challenge. This study investigated the renoprotective effects of Valsartan, Leucovorin and their combination in mitigating methotrexate (MTX)-induced renal damage in Wistar rats. The aim was to evaluate these effects in a rat model of MTX-induced acute kidney injury (AKI). After approval by the Institutional Animal Ethics Committee (IAEC), forty male Wistar rats were divided into five groups: control (saline), MTX (single intraperitoneal injection of 20 mg/kg), Valsartan (10 mg/kg/day), leucovorin (10 mg/kg/day), and combination (Valsartan plus leucovorin). Drug treatment was initiated one day before MTX administration and continued orally for five days. Renal function was assessed by measuring serum creatinine and blood urea nitrogen (BUN). Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were evaluated as inflammatory markers, while malondialdehyde (MDA) and glutathione (GSH) were assessed as oxidative stress markers. Histopathological examination of renal tissue was also performed. Data were analyzed using GraphPad Prism version 6. The MTX group showed significant renal dysfunction (p < 0.001) and increased inflammatory and oxidative stress markers. Both Valsartan and leucovorin produced partial renoprotective effects, with Valsartan significantly reducing oxidative stress (p < 0.001) and leucovorin markedly decreasing inflammatory markers (p < 0.001). The combination therapy demonstrated the most pronounced renoprotective effect (p < 0.001), as evidenced by improved renal function and reduced oxidative damage and inflammation. Histopathological analysis revealed decreased tubular necrosis and inflammatory infiltration in the combination group. Valsartan and leucovorin exerted individual renoprotective effects; however, their combined administration provided highly significant protection against MTX-induced AKI. These findings suggest that combination therapy may represent a promising strategy for preventing renal injury in patients undergoing MTX treatment.

3 March 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JDJayshree Dawane
Jayshree Dawane
PDPriti Dhande
Priti Dhande
CSChandra Dhar Shukla
Chandra Dhar Shukla
ADAishwarya Dhakne
Aishwarya Dhakne
Introduction: Revstone ®, a polyherbal formulation available in capsule and syrup forms, is designed to treat kidney-related disorders. However, its renoprotective efficacy remains insufficiently validated. In this study, we aimed to evaluate and compare the renoprotective potential of Revstone ® capsule and syrup formylations in Wistar rats. Objective: The aim of this study was to assess the acute toxicity profile of Revstone ® capsule and syrup following Organisation for Economic Co-operation and Development (OECD) guidelines and compare their efficacy in reversing renal damage based on biochemical, histological, and functional markers. Methodology: Acute oral toxicity testing was conducted according to the OECD 423 guidelines, and rats were observed for 14 days for mortality, behavioural and clinical changes, body weight variations, and gross necropsy findings. For efficacy evaluation, nephrotoxicity was induced by gentamicin (80 mg/kg i.p. for 7 days). Rats were divided into seven groups, namely, the normal control, disease control, Revstone ® syrup (low and high dose), Revstone ® capsule (low and high dose), and standard drug control (valsartan 10 mg/kg). Renal function was assessed from serum creatinine, blood urea nitrogen, and uric acid levels. Oxidative stress markers such as malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) were measured, and histopathological evaluation of kidney tissue was performed. Data were analysed using one-way ANOVA followed by Tukey’s post hoc test ( p < 0.05). Results: Gentamicin significantly elevated renal markers ( p < 0.001). Revstone ® syrup at high dose markedly reduced creatinine ( p < 0.001), while both formulations improved oxidative stress and renal histology. The syrup formulation was more effective, indicating its potential for future clinical application. Conclusion: Revstone ® capsule and syrup demonstrated significant renoprotective activities in gentamicin-induced nephrotoxicity in rats.

30 September 2024 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
JDJayshree Dawane
Jayshree Dawane
PDPriti Pravin Dhande
Priti Pravin Dhande
Drakshasava is a formulation used as a general tonic also for anxiety, anaemia in the Ayurveda. Our previous study reports for antidepressant property were very promising. This study aims to elucidate the antidepressant mechanisms of Drakshasava by examining its effects on key neurotransmitters and stress hormones, as well as observing related behavioral changes in Wistar rats under stress models. Methods: Wistar rats weighing 150-200 gms were divided into six groups consisting of 6 rats in each group. Two animal models, acute stress (AS) and unpredictable chronic mild stress (UCMS) were used. Drug treatment was given as per groups orally, Drakshasava in the dose of 2ml & 4ml/kg and Fluoxetine standard comparator 10mg/kg for next 7 days for AS. In UCMS group stress was given for 15 days and drug treatment was given along with the stress from day 15-21. Sucrose preference test (SPT) done on day 0 & 8 in AS and on day 0, 15, 22 in UCMS model rats and at the end Forced Swim test (FST) was performed. Blood withdrawal done for estimation of serum Dopamine, Serotonin and cortisol levels with ELISA kit on day 8 in AS & 22 in UCMS. Data obtained analysed with Graph Pad Prism 6. Result: Decrease in Dopamine (p<0.05) and Serotonin (p<0.01) while increase (p<0.01) in cortisol levels was seen in (depressed) disease control group rats in comparison with control group. Both doses of Drakshasava showed significant reduction in immobility time in FST and improved sucrose preference and was found to be effective in both the models of depression. Increase in serum serotonin (p<0.01) and dopamine (p<0.05) levels was evident while at the same time, (p<0.05) cortisol level reduction was seen in all drug treated rats. Findings observed in the FST and SPT were correlated with the biochemical findings. Effects seen with Drakshasava were comparable with that of Fluoxetine. Conclusion: Drakshasava increased serum serotonin and dopamine levels while decreasing cortisol levels in both acute and chronic animal models of depression. These effects were comparable to those observed with the standard antidepressant drug, Fluoxetine.